Helus Pharma Enrolls Phase 3 Trial for Depression Drug HLP003
Helus Pharma completes enrollment in Phase 3 APPROACH trial for HLP003, a deuterated psilocin analogue for major depressive disorder. Topline results expected Q4 2026.
This news matters because major depressive disorder affects millions worldwide, and current treatments fail many patients. If HLP003 proves successful, it could offer a new, potentially faster-acting and longer-lasting option for those who do not respond to existing antidepressants, addressing a critical gap in mental health care.
